Cognitive interventions in Alzheimer's and Parkinson's diseases: emerging mechanisms and role of imaging

被引:15
|
作者
Vemuri, Prashanthi [1 ]
Fields, Julie [2 ]
Peter, Jessica [3 ]
Kloeppel, Stefan [3 ,4 ]
机构
[1] Mayo Clin, Dept Radiol, Rochester, MN USA
[2] Mayo Clin, Div Neurocognit Disorders, Rochester, MN USA
[3] Univ Med Ctr Freiburg, Dept Psychiat & Psychotherapy, Freiburg, Germany
[4] Univ Med Ctr Freiburg, Ctr Geriatr & Gerontol, Freiburg, Germany
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; cognitive training; imaging; neuroplasticity; Parkinson's disease; WHITE-MATTER PLASTICITY; NORMAL OLDER-ADULTS; OF-THE-LITERATURE; WORKING-MEMORY; CLINICAL-TRIALS; CORTICOSPINAL TRACT; AMYLOID DEPOSITION; CEREBRAL PERFUSION; BRAIN PLASTICITY; IMPAIRMENT;
D O I
10.1097/WCO.0000000000000346
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose of review There has been recent debate about the lack of compelling scientific evidence on the efficacy of cognitive interventions. The goal of this study is to review the current state of cognitive interventions in Alzheimer's disease and Parkinson's disease, present emerging mechanisms, and discuss the role of imaging in designing effective intervention strategies. Recent findings Cognitive interventions appear to be promising in Alzheimer's disease and Parkinson's disease. Although feasibility has been shown in mild cognitive impairment, early Alzheimer's disease, and mild to moderate Parkinson's disease, studies to investigate long-term efficacy and mechanisms underlying these interventions are still needed. Summary There is a need to conduct scientifically rigorous studies to validate the efficacy of cognitive intervention trials. Future studies will greatly benefit from including longitudinal imaging in their study design. Imaging can be used to demonstrate the efficacy and mechanisms by measuring brain changes over the intervention period. Imaging can also be used to determine biological and disease-related factors that may influence the treatment response, that is, the effect modifiers. Consideration of effect modifiers will allow us to measure the treatment response in biomarkers and cognition with greater sensitivity and also aid in designing trials that will lead to better patient outcomes.
引用
收藏
页码:405 / 411
页数:7
相关论文
共 50 条
  • [31] Herpesviruses in brains in Alzheimer's and Parkinson's diseases
    Hemling, N
    Röyttä, M
    Rinne, J
    Pöllänen, P
    Broberg, E
    Tapio, V
    Vahlberg, T
    Hukkanen, V
    ANNALS OF NEUROLOGY, 2003, 54 (02) : 267 - 271
  • [32] Sleep Disturbances in Alzheimer’s and Parkinson’s Diseases
    Sarah M. Rothman
    Mark P. Mattson
    NeuroMolecular Medicine, 2012, 14 : 194 - 204
  • [33] Neuropathological hallmarks of Alzheimer's and Parkinson's diseases
    Braak, H
    de Vos, RAI
    Jansen, ENH
    Bratzke, H
    Braak, E
    NEURONAL DEGENERATION AND REGENERATION: FROM BASIC MECHANISMS TO PROSPECTS FOR THERAPY, 1998, 117 : 267 - 285
  • [34] Proposed biochemistry of Parkinson's and Alzheimer's diseases
    Robertson, D. S.
    MEDICAL HYPOTHESES, 2017, 109 : 131 - 138
  • [35] Perceptual priming in Alzheimer's and Parkinson's diseases
    Koivisto, M
    Portin, R
    Rinne, JO
    NEUROPSYCHOLOGIA, 1996, 34 (05) : 449 - 457
  • [36] The Evolution of Genetics: Alzheimer's and Parkinson's Diseases
    Singleton, Andrew
    Hardy, John
    NEURON, 2016, 90 (06) : 1154 - 1163
  • [37] Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer’s and Parkinson’s diseases
    Makoto Hashimoto
    Edward Rockenstein
    Leslie Crews
    Eliezer Masliah
    NeuroMolecular Medicine, 2003, 4 : 21 - 35
  • [38] Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases
    Hashimoto, M
    Rockenstein, E
    Crews, L
    Masliah, E
    NEUROMOLECULAR MEDICINE, 2003, 4 (1-2) : 21 - 35
  • [39] Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimer's and Parkinson's Diseases
    Srivastava, Sarika
    Haigis, Marcia C.
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (31) : 3418 - 3433
  • [40] Mitochondria in the pathophysiology of Alzheimer's and Parkinson's diseases
    Onyango, Isaac G.
    Khan, Shaharyar M.
    Bennett, James P., Jr.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2017, 22 : 854 - 872